Trials / Completed
CompletedNCT00144599
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 2 Years – 19 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, Phase III study to evaluate the efficacy, safety and PK of MRA in patients with sJIA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRA(Tocilizumab) | |
| DRUG | placebo |
Timeline
- Start date
- 2004-05-01
- Completion
- 2005-10-01
- First posted
- 2005-09-05
- Last updated
- 2008-07-30
Source: ClinicalTrials.gov record NCT00144599. Inclusion in this directory is not an endorsement.